Drug profile

The FDA adverse-event record for Clostridium Chauvoei + Clostridium Haemolyticum + Clostridium Novyi + Clostridium Perfringens Type C + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii

Name: Clostridium Chauvoei + Clostridium Haemolyticum + Clostridium Novyi + Clostridium Perfringens Type C + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Clostridium Chauvoei + Clostridium Haemolyticum + Clostridium Novyi + Clostridium Perfringens Type C + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii. See the species affected, top reactions, and outcomes below.

10
adverse-event reports: 30.0%
death-coded share: Cattle
most-reported species: 3
Lack of efficacy - NOS - top reaction

Compiled by PlainBreed Editorial, Pet Health Editorial Team

Verify with FDA CVM →

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

30.0%

Death Rate

Active Ingredients

Clostridium ChauvoeiClostridium HaemolyticumClostridium NovyiClostridium Perfringens Type CClostridium Perfringens Type D Bacterin ToxoidClostridium SepticumClostridium Sordellii

Administration Routes

UnknownSubcutaneous

Species Affected

Cattle 10

Most Affected Breeds

Cattle (other) 10

Most Reported Reactions

Lack of efficacy - NOS 3

Death 2

Rectal prolapse 2

Anaphylaxis 1

INEFFECTIVE, PARASITE(S) 1

Pink eye 1

INEFFECTIVE, KCS 1

Lameness 1

Pneumonia 1

Skin abscess 1

Laceration 1

Unrelated death 1

Outcome Breakdown

Recovered/Normal

4 (36.4%)

Died

3 (27.3%)

Ongoing

2 (18.2%)

Outcome Unknown

2 (18.2%)

Clostridium Chauvoei + Clostridium Haemolyticum + Clostridium Novyi + Clostridium Perfringens Type C + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii Adverse Event Insights

10 reports name Clostridium Chauvoei + Clostridium Haemolyticum + Clostridium Novyi + Clostridium Perfringens Type C + Clostridium Perfringens Type D Bacterin Toxoid + Clostridium Septicum + Clostridium Sordellii; 3 recorded a death outcome (30.0% of reported events, not a population-level mortality rate). Active ingredients: Clostridium Chauvoei, Clostridium Haemolyticum, Clostridium Novyi, Clostridium Perfringens Type C, Clostridium Perfringens Type D Bacterin Toxoid. Administration routes: Unknown, Subcutaneous.

By species: Cattle (10 reports). By breed: Cattle (other) (10).

Leading clinical signs: Lack of efficacy - NOS (3), Death (2), Rectal prolapse (2), Anaphylaxis (1). Outcome, 11 coded reports: Recovered/Normal leads at 36.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.